Stockscreener 앱 받기
1.88
0.53%
-0.01
시간 외 거래:
1.93
0.05
+2.66%
전일 마감가:
$1.89
열려 있는:
$1.91
하루 거래량:
378.26K
Relative Volume:
0.40
시가총액:
$108.01M
수익:
$70.00M
순이익/손실:
$-43.21M
주가수익비율:
-2.4805
EPS:
-0.7579
순현금흐름:
$-34.03M
1주 성능:
-4.08%
1개월 성능:
-16.07%
6개월 성능:
-14.16%
1년 성능:
-39.55%
1일 변동 폭
$1.85
$1.915
1주일 범위
$1.83
$1.995
52주 변동 폭
$1.60
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
명칭
Black Diamond Therapeutics Inc
전화
617-417-5868
주소
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.88 | 108.59M | 70.00M | -43.21M | -34.03M | -0.7579 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-11-18 | 재개 | Piper Sandler | Overweight |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2024-07-31 | 개시 | Raymond James | Outperform |
| 2023-07-14 | 개시 | Piper Sandler | Overweight |
| 2023-06-30 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-03-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-03-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-01-07 | 개시 | Wedbush | Outperform |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | Canaccord Genuity | Buy |
| 2020-02-24 | 개시 | Cowen | Outperform |
| 2020-02-24 | 개시 | JP Morgan | Overweight |
| 2020-02-24 | 개시 | Jefferies | Buy |
모두보기
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees - Stock Titan
Black Diamond Therapeutics (BDTX) director opts for 6,801 shares instead of cash - Stock Titan
Black Diamond Therapeutics, Inc.Common Stock (NQ: BDTX - The Chronicle-Journal
BDTX Q2 2026 Earnings: Narrower Loss of -$0.17 Beats Estimates, Yet Shares SlipRevenue Inflection Point - careplusvn.com
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.9% Share GainProfit Margin Analysis - vinanet.vn
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
BDTX Q2 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineROA Comparison - vinanet.vn
BDTX Q2 2026 Earnings: EPS Beat of 14.7% Overshadowed by 4.7% Share DeclineCapex Guidance - vinanet.vn
Black Diamond Therapeutics (BDTX) Dips 1.76% as Shares Test Key Support ZoneArms Index - vinanet.vn
Black (BDTX) Q2 2026 Results: EPS Comes in Above Forecast for the Current Session; Latest Reaction: Shares Finish 4.34% Lower in the Available RecordReturn On Assets - vinanet.vn
Black (BDTX) Move: Moves 4.16% Lower to $2.10 in Latest Trading; Levels: Traders Can Monitor the $1.99-$2.21 Range under the Current SnapshotVolume Rate Change - vinanet.vn
Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest TradingProfit Growth Outlook - vinanet.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX? - StockInvest.us
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com
BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.56%Mid-Term Outlook - vinanet.vn
Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView
Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat
Black Diamond Therapeutics Inc (BDTX) Stock News Today - TradingKey
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $14 - Moomoo
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 Earnings Forecast for BDTX Issued By HC Wainwright - MarketBeat
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $11 - Moomoo
Raymond James Reaffirms Outperform on BDTX Amid Promising NSCLC Trial Data - GuruFocus
Jefferies Optimistic on BDTX Ahead of Q4 Catalysts; Shares Trade Near 1-Year Low - GuruFocus
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond Therapeutics (NASDAQ:BDTX) Posts Earnings Results - MarketBeat
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics reports Q2 2026: $110.5M cash, $9.9M net loss - TradingView
Black Diamond Therapeutics, Inc. 2Q 2026: Revenue $0 Net income ($9.91M), EPS ($0.17) — 10-Q Summary - TradingView
Black Diamond Therapeutics Q2 net loss narrows year over year - TradingView
BDTX: Silevertinib demonstrated robust Phase 2 efficacy in NSCLC, supporting pivotal development plans - TradingView
Black Diamond Therapeutics (NASDAQ: BDTX) details Q2 loss and 2028 cash runway - Stock Titan
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Black Diamond Therapeutics Q2 net loss narrows to $9.91 million; revenue remains no revenue - Bitget
BDTX Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Black Diamond Therapeutics Inc (BDTX) Institutional Confidence - TradingKey
BDTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
BDTX|Black Diamond Therapeutics Inc|Price:1.730|Chg%:-0.030 - TradingKey
Black Diamond Therapeutics (BDTX): BlackRock discloses 3.84M-share, 6.7% ownership - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics, Inc. Revenue Breakdown – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.770|Chg%:+0.040 - TradingKey
Black Diamond Therapeutics Inc (BDTX) Balance Sheet - TradingKey
Black Diamond Therapeutics Inc (BDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):